RenovoRx, Inc. (RNXT) Earnings Call Analysis

NASDAQ · Unknown · Unknown

20/25

Growth 5 Margin 5 Expansion 3 Platform 5 Financial 2

latest quarter score

Earnings Reports

20
RenovoRx (RNXT) Q2 2026: 31% Customer Funnel Expansion Signals Commercial Inflection
August 13, 2026
17
RenovoRx (RNXT) Q1 2026: Active Cancer Centers Double to 16, Catalyzing Commercial Inflection
May 15, 2026
13
RenovoRx (RNXT) Q4 2025: Active Site Pipeline Triples, Anchoring $3-4M Revenue Target
March 31, 2026
11
RenovoRx (RNXT) Q3 2025: 24 Center Pipeline Signals Commercial Inflection Ahead of TIGER-PAC Data
November 13, 2025
17
RenovaRx (RNXT) Q2 2025: RenovoCath Sales Reach $422K as Phase 3 Trial Advances Without Data Bias
August 15, 2025
11
RenovoRx (RNXT) Q1 2025: RenovoCath Commercial Sales Exceed Expectations, Signaling Growth Trajectory
May 15, 2025

Browse all companies